Compare CCM & CLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCM | CLGN |
|---|---|---|
| Founded | 1997 | 2004 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.8M | 23.1M |
| IPO Year | 2009 | N/A |
| Metric | CCM | CLGN |
|---|---|---|
| Price | $4.25 | $1.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | 3.2K | ★ 24.0K |
| Earning Date | 09-26-2025 | 11-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $51,056,841.00 | $2,475,000.00 |
| Revenue This Year | N/A | $1,617.28 |
| Revenue Next Year | N/A | $83.54 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 280.77 |
| 52 Week Low | $3.54 | $1.31 |
| 52 Week High | $10.77 | $4.98 |
| Indicator | CCM | CLGN |
|---|---|---|
| Relative Strength Index (RSI) | 47.23 | 24.98 |
| Support Level | $4.12 | $1.77 |
| Resistance Level | $4.99 | $1.93 |
| Average True Range (ATR) | 0.26 | 0.14 |
| MACD | 0.10 | -0.06 |
| Stochastic Oscillator | 48.96 | 0.00 |
Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Its network includes radiotherapy centers, diagnostic imaging centers, and centers providing other treatment and diagnostic services.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.